These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 16259756

  • 1. In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan.
    Hao YL, Deng YJ, Chen Y, Wang KZ, Hao AJ, Zhang Y.
    J Pharm Pharmacol; 2005 Oct; 57(10):1279-87. PubMed ID: 16259756
    [Abstract] [Full Text] [Related]

  • 2. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
    Dadashzadeh S, Vali AM, Rezaie M.
    Int J Pharm; 2008 Apr 02; 353(1-2):251-9. PubMed ID: 18191511
    [Abstract] [Full Text] [Related]

  • 3. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
    Chow TH, Lin YY, Hwang JJ, Wang HE, Tseng YL, Wang SJ, Liu RS, Lin WJ, Yang CS, Ting G.
    Anticancer Res; 2009 Jun 02; 29(6):2111-20. PubMed ID: 19528471
    [Abstract] [Full Text] [Related]

  • 4. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
    Li C, Wang C, Yang H, Zhao X, Wei N, Cui J.
    J Pharm Pharmacol; 2012 Mar 02; 64(3):372-82. PubMed ID: 22309269
    [Abstract] [Full Text] [Related]

  • 5. In vitro and in vivo studies of different liposomes containing topotecan.
    Hao YL, Deng YJ, Chen Y, Wang XM, Zhong HJ, Suo XB.
    Arch Pharm Res; 2005 May 02; 28(5):626-35. PubMed ID: 15974453
    [Abstract] [Full Text] [Related]

  • 6. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J, Li C, Guo W, Li Y, Wang C, Zhang L, Zhang L, Hao Y, Wang Y.
    J Control Release; 2007 Apr 02; 118(2):204-15. PubMed ID: 17239468
    [Abstract] [Full Text] [Related]

  • 7. Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts.
    Zamboni WC, Strychor S, Joseph E, Walsh DR, Zamboni BA, Parise RA, Tonda ME, Yu NY, Engbers C, Eiseman JL.
    Clin Cancer Res; 2007 Dec 01; 13(23):7217-23. PubMed ID: 18056203
    [Abstract] [Full Text] [Related]

  • 8. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
    Hong RL, Huang CJ, Tseng YL, Pang VF, Chen ST, Liu JJ, Chang FH.
    Clin Cancer Res; 1999 Nov 01; 5(11):3645-52. PubMed ID: 10589782
    [Abstract] [Full Text] [Related]

  • 9. Long-circulating liposome-encapsulated ganciclovir enhances the efficacy of HSV-TK suicide gene therapy.
    Kajiwara E, Kawano K, Hattori Y, Fukushima M, Hayashi K, Maitani Y.
    J Control Release; 2007 Jul 16; 120(1-2):104-10. PubMed ID: 17509714
    [Abstract] [Full Text] [Related]

  • 10. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
    Ogawara K, Un K, Tanaka K, Higaki K, Kimura T.
    J Control Release; 2009 Jan 05; 133(1):4-10. PubMed ID: 18840484
    [Abstract] [Full Text] [Related]

  • 11. Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice.
    Li X, Lu WL, Liang GW, Ruan GR, Hong HY, Long C, Zhang YT, Liu Y, Wang JC, Zhang X, Zhang Q.
    Eur J Clin Invest; 2006 Jun 05; 36(6):409-18. PubMed ID: 16684125
    [Abstract] [Full Text] [Related]

  • 12. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
    Gabizon AA, Tzemach D, Horowitz AT, Shmeeda H, Yeh J, Zalipsky S.
    Clin Cancer Res; 2006 Mar 15; 12(6):1913-20. PubMed ID: 16551877
    [Abstract] [Full Text] [Related]

  • 13. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan.
    Emerson DL, Bendele R, Brown E, Chiang S, Desjardins JP, Dihel LC, Gill SC, Hamilton M, LeRay JD, Moon-McDermott L, Moynihan K, Richardson FC, Tomkinson B, Luzzio MJ, Baccanari D.
    Clin Cancer Res; 2000 Jul 15; 6(7):2903-12. PubMed ID: 10914740
    [Abstract] [Full Text] [Related]

  • 14. Lipid composition and grafted PEG affect in vivo activity of liposomal mitoxantrone.
    Li C, Cui J, Wang C, Wang J, Li Y, Zhang L, Zhang L, Guo W, Wang Y.
    Int J Pharm; 2008 Oct 01; 362(1-2):60-6. PubMed ID: 18598745
    [Abstract] [Full Text] [Related]

  • 15. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome.
    Suzuki R, Takizawa T, Kuwata Y, Mutoh M, Ishiguro N, Utoguchi N, Shinohara A, Eriguchi M, Yanagie H, Maruyama K.
    Int J Pharm; 2008 Jan 04; 346(1-2):143-50. PubMed ID: 17640835
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin.
    Hong M, Zhu S, Jiang Y, Tang G, Pei Y.
    J Control Release; 2009 Jan 19; 133(2):96-102. PubMed ID: 18840485
    [Abstract] [Full Text] [Related]

  • 19. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
    Tuscano JM, Martin SM, Ma Y, Zamboni W, O'Donnell RT.
    Clin Cancer Res; 2010 May 15; 16(10):2760-8. PubMed ID: 20460479
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.